Rutherford W E, Blondin J, Hruska K, Kopelman R, Klahr S, Slatopolsky E
Kidney Int. 1975 Nov;8(5):320-4. doi: 10.1038/ki.1975.119.
Calcium absorption was measured in eight uremic patients before and after eight days of treatment with 100 or 500 mug of 25-hydroxycholecalciferol (25(OH)D3) per day. Fractional calcium absorption was estimated by administering 47Ca i.v. and orally on separate days and counting forearm radioactivity four hours later. Calcium absorption in four patients with residual renal function rose from 16.3 +/- 2.5 to 40.8 +/- 5.5% after treatment. In order to determine if the increased calcium absorption was mediated by an increase in the production of 1,25-dihydroxycholecalciferol (1,25(OH)2D3) by virtue of increased substrate delivery to the 25-hydroxycholecalciferol-1-hydroxylase system present in the residual renal tissue, identical studies were performed in four anephric patients. Calcium absorption in these patients averaged 15.7 +/- 2.2% during the control period and rose to 46.0 +/- 11.1% after treatment. Increments in serum calcium after treatment were similar in both groups of patients; the mean concentration rose from 9.6 +/- 0.3 to 11.0 +/- 0.6 mg/100 ml. The results indicate that 25(OH)D3 can improve calcium absorption in the absence of renal tissue suggesting that its conversion to 1,25(OH)2D3 may not be necessary for its effect on the gastrointestinal tract in the uremic patient.
对8名尿毒症患者在每日给予100或500微克25 - 羟胆钙化醇(25(OH)D3)治疗8天前后进行钙吸收测定。通过在不同日期静脉注射和口服47Ca并于4小时后计数前臂放射性来估算钙的吸收分数。4名仍有残余肾功能的患者经治疗后钙吸收从16.3±2.5%升至40.8±5.5%。为确定钙吸收增加是否是由于向残余肾组织中存在的25 - 羟胆钙化醇 - 1 - 羟化酶系统提供了更多底物从而使1,25 - 二羟胆钙化醇(1,25(OH)2D3)生成增加所介导,对4名无肾患者进行了相同研究。这些患者在对照期钙吸收平均为15.7±2.2%,治疗后升至46.0±11.1%。两组患者治疗后血清钙的升高相似;平均浓度从9.6±0.3毫克/100毫升升至11.0±0.6毫克/100毫升。结果表明,在无肾组织的情况下25(OH)D3可改善钙吸收,这提示其对尿毒症患者胃肠道的作用可能并不需要转化为1,25(OH)2D3。